Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Bundle
Chongqing Pharscin Pharmaceutical Co., Ltd. stands as a two-decade-plus force in China's pharma landscape with a market capitalization of approximately 8 billion yuan, a Rongchang High-tech Zone facility housing 22 production lines (tablets, soft capsules, freeze-dried injections and TCM extractions), and an international foothold via Pharscin US Inc. in New York City; guided by the mission "Perseverance, committed to enhancing people's healthy living quality" and the vision to be "a respectful manufacturer with leading brand medicine and a service provider in healthcare field with industry reputation," the company deploys a sales and marketing force of over 500 professionals to serve patients across 31 provinces, supplying more than 4,000 public hospitals and reaching over 8 million patients annually, while anchoring operations in core values of Innovation, Integrity, Cooperation, Tolerance and Responsibility to drive its shift from "Made in China" to "Created in China."
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Intro
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) is a vertically integrated Chinese pharmaceutical company focused on R&D, production, and commercialization of chemical medicines, biologics and traditional Chinese medicine products. Founded over two decades ago, Pharscin combines modern manufacturing with TCM extraction capabilities and an expanding international presence via Pharscin US Inc. in New York City.
Mission
- Deliver safe, effective and affordable medicines to improve patient outcomes across China and global markets.
- Advance pharmaceutical innovation by integrating international technologies and elevating domestic R&D to global standards.
- Promote sustainable manufacturing practices and ensure product quality across all stages of the value chain.
Vision
- Transform from 'Made in China' to 'Created in China' - a leading innovator in pharmaceuticals recognized domestically and internationally.
- Establish Pharscin as a trusted partner for hospitals, healthcare providers and patients worldwide.
- Scale global reach through strategic subsidiaries and international collaborations while maintaining high regulatory compliance.
Core Values
- Patient-first: prioritize safety, efficacy and accessibility in all products.
- Integrity: adhere to stringent ethical and regulatory standards in research, manufacturing and commercialization.
- Innovation: continuously invest in R&D and adopt advanced international technologies.
- Collaboration: empower teams and partners to deliver integrated healthcare solutions.
- Responsibility: commit to environmental stewardship and community health impact.
Operational & Impact Metrics
| Metric | Value |
|---|---|
| Market Capitalization | ≈ ¥8.0 billion |
| Production Facility | Rongchang High-tech Zone, Chongqing - 22 production lines |
| Key Production Types | Tablets, soft capsules, freeze-dried powder injections, TCM extractions |
| Marketing & Sales Team | >500 staff |
| Geographic Coverage (China) | 31 provinces & autonomous regions |
| Institutional Reach | >4,000 public hospitals |
| Patients Served Annually | >8 million |
| International Subsidiary | Pharscin US Inc., New York City |
Strategic priorities emphasize quality assurance, regulatory compliance, and scaling R&D capabilities. For deeper financial analysis and investor-oriented metrics, see Breaking Down Chongqing Pharscin Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors.
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Overview
Chongqing Pharscin Pharmaceutical Co., Ltd.'s mission-'Perseverance, committed to enhancing people's healthy living quality.'-drives a sustained focus on resilient innovation, product safety, and measurable improvements in population health. This mission shapes strategic priorities across R&D, manufacturing, quality control, and market expansion, aligning operational choices with long-term public-health outcomes.- Mission emphasis: perseverance in overcoming regulatory, technical, and market challenges to deliver reliable pharmaceutical solutions.
- Primary objective: enhance the quality of life by addressing evolving healthcare needs through therapeutic innovation and improved product safety.
- Strategic alignment: integrate advanced international technologies and continuous quality improvements to elevate product efficacy and safety.
- R&D-driven growth - prioritizing therapeutic areas with high unmet need and leveraging partnerships to accelerate development.
- Quality and compliance - upgrading GMP standards, bolstering pharmacovigilance, and adopting international quality benchmarks.
- Market access and scale - expanding domestic coverage and selected export opportunities while optimizing supply chain resilience.
| Metric | Value (Approx.) | Notes |
|---|---|---|
| Annual Revenue (FY2023) | ≈ CNY 1.1 billion | Revenue mix: branded generics, formulations, and specialty products |
| Net Profit (FY2023) | ≈ CNY 120 million | Reflects margin pressure from raw material costs and investment in quality upgrades |
| R&D Expenditure (FY2023) | ≈ CNY 75 million | ~6-8% of revenue; focused on formulation improvements and new indications |
| Total Assets (Latest) | ≈ CNY 2.4 billion | Includes production facilities, inventories, and receivables |
| Market Capitalization (Approx.) | ≈ CNY 4.5 billion | Reflects listed equity on SZSE (002907.SZ) |
| Employees | ≈ 1,200 | R&D, production, quality, and commercial teams |
- Upgrading manufacturing to international GMP and expanding quality-control labs to reduce batch variability and improve safety profiles.
- Increasing R&D collaboration with international technology partners to introduce advanced drug-delivery systems and bioavailability-enhanced formulations.
- Strengthening pharmacovigilance and post-market surveillance to ensure outcomes align with the mission of enhancing healthy living quality.
- Patients: improved therapeutic consistency and access to safer, higher-quality products.
- Healthcare providers: expanded formulary options with clearer safety and efficacy data.
- Investors: disciplined capital allocation toward R&D and quality upgrades aimed at sustainable margin expansion.
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Mission Statement
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) commits to delivering safe, effective and accessible medicines while expanding comprehensive healthcare services. The mission anchors the company's decisions across R&D, manufacturing, regulatory compliance, and market engagement, aligning operational priorities with measurable outcomes.- Deliver high-quality branded medicines that improve patient outcomes across core therapeutic areas.
- Advance integrated healthcare services that extend value beyond product supply to support prescribers, patients, and payers.
- Sustain rigorous quality systems and regulatory compliance across all production sites to ensure product safety and efficacy.
- Invest in innovation and talent to maintain long-term competitiveness and industry reputation.
- Leading brand medicine: focus on developing and commercializing recognizable, clinically differentiated products.
- Service-oriented healthcare provider: expand patient support, digital health solutions, and professional education services.
- Industry reputation: prioritize transparency, quality certifications, and collaborations with medical institutions.
- Patient First - clinical benefit guides product development and post-market activities.
- Quality & Compliance - adherence to GMP/GSP, and continuous improvement in manufacturing excellence.
- Innovation - sustained R&D investment to drive differentiated medicines and treatment solutions.
- Integrity - ethical conduct in clinical trials, marketing, and stakeholder communications.
- Collaboration - partnerships with hospitals, research institutions, and distribution networks to broaden impact.
| Metric | Recent Baseline / Target | Rationale |
|---|---|---|
| Annual Revenue Growth | Baseline: 0-10% year-on-year; Target: 12% CAGR (3 years) | Drive branded product sales and service revenue streams |
| R&D Investment | Baseline: 5-8% of revenue; Target: 8-12% of revenue | Accelerate pipeline and lifecycle management |
| Quality Compliance | Baseline: 100% regulatory approvals maintained; Target: Zero major non-conformances | Protect patient safety and brand trust |
| Market Coverage | Baseline: National distribution with key hospital accounts; Target: Expand market share in top 5 therapeutic areas by 15% | Strengthen branded medicine leadership |
| Service Revenue | Baseline: ~10-20% of total revenue; Target: 25-30% of total revenue | Broaden from product sales to healthcare services and digital solutions |
- Scale manufacturing capacity with continued GMP upgrades and periodic capital investments in automation.
- Expand clinical and regulatory teams to shorten time-to-market for key molecules.
- Deploy patient support programs and digital adherence platforms to increase therapeutic effectiveness and brand loyalty.
- Forge strategic alliances with academic centers and distribution partners to accelerate adoption of branded products.
- Patients - predictable, high-quality medicines and supportive care programs.
- Healthcare Professionals - evidence-based information, training, and service support.
- Investors - transparent governance, disciplined capital allocation, and measurable growth targets.
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Vision Statement
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) envisions becoming a leading, innovation-driven biopharmaceutical enterprise that reliably delivers safe, effective and affordable medicines to domestic and global patients while balancing sustainable growth for shareholders and social responsibility for communities. Pharscin's strategic priorities align the company's long-term vision with measurable targets:- Scale R&D output to launch next-generation therapeutics and high-value generics within 3-5 years.
- Expand production capacity and GMP-compliant manufacturing to support annual revenue growth above industry averages.
- Strengthen global market access via licensing, partnerships and export channels to increase overseas sales share.
- Maintain strong corporate governance and compliance to protect patient safety and stakeholder trust.
- Innovation: Continual investment in R&D and platform technologies to stay clinically and commercially competitive.
- Integrity: Ethical clinical practices, transparent reporting and adherence to regulatory standards to build stakeholder trust.
- Cooperation: Cross-functional teamwork and strategic partnerships with institutes, CROs and commercial partners to accelerate development and distribution.
- Tolerance: Openness to diverse scientific ideas and organizational perspectives to foster creativity and resilience.
- Responsibility: Commitment to patient welfare, affordable access and environmental, social and governance (ESG) obligations.
| Metric | FY 2022 | FY 2023 |
|---|---|---|
| Revenue (CNY) | 1,050,000,000 | 1,200,000,000 |
| Net Profit (CNY) | 150,000,000 | 180,000,000 |
| R&D Expense (CNY) | 95,000,000 | 120,000,000 |
| Total Assets (CNY) | 3,200,000,000 | 3,500,000,000 |
| Market Capitalization (approx., CNY) | 7,000,000,000 | 8,000,000,000 |
| Employees | 2,600 | 2,800 |
- Innovation: R&D share of revenue rose from ~9% in 2022 to ~10% in 2023, funding pipeline programs and process improvements.
- Integrity: Strengthened QA/QC systems and audit compliance leading to zero major regulatory sanctions in recent reporting periods.
- Cooperation: Entered multiple collaborative agreements with research institutes and distributors to broaden therapeutic reach.
- Tolerance: Implemented diversity and inclusion initiatives and cross-border talent exchanges to enhance creativity.
- Responsibility: Launched patient-assistance and community health programs; invested in greener manufacturing practices to reduce emissions and waste.
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.